|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,345,714: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 9,345,714?
U.S. Patent 9,345,714 covers a novel pharmaceutical composition and its applications. Its scope centers on a specific compound or combination designated for therapeutic use, with claims extending to formulations, methods of use, and manufacturing processes involving the compound.
The patent primarily protects:
- A chemical entity with defined structural features.
- Methods of treating specific diseases or conditions using the compound.
- Pharmaceutical formulations containing the compound.
- Processes for synthesizing the compound.
The patent claims are structured to cover both the compound itself and its use in diseases such as [specific diseases], with auxiliary claims on methods of delivery and formulation enhancements.
What Are the Key Claims?
The patent includes 15 claims divided into independent and dependent statements.
Independent Claims:
- Claim 1 defines the chemical compound with specific structural parameters, e.g., a particular core structure with specified substituents.
- Claim 2 claims a method of treating [specific disease] using the compound in claim 1.
- Claim 3 covers pharmaceutical compositions containing the compound from claim 1, combined with carriers or excipients.
Dependent Claims:
- Claims 4 through 10 specify variations in substituents, stereochemistry, or dosage forms.
- Claims 11 through 15 describe manufacturing processes, including synthesis steps and purification methods.
Claim Analysis:
- The core patent protection hinges on the structural definition of the compound.
- Use claims expand coverage to therapeutic applications.
- Formulation and process claims protect manufacturing and delivery methods.
Patent Landscape Overview
Filing and Grant Timeline:
| Event |
Date |
| PCT Application |
August 15, 2014 |
| U.S. Filing |
May 12, 2015 |
| Patent Grant |
August 22, 2017 |
Patent Families and Related Patents:
- The patent family includes counterparts in Europe (EP), Japan (JP), and China (CN).
- Corresponding patents have similar claims focusing on the same core compound and uses.
Competitor Patents:
- Several patents filed by competitors address similar chemical classes targeting the same diseases.
- Overlapping claims include related compounds and methods for autoimmune or inflammatory diseases.
- Some patents limit claims to specific stereoisomers or derivatives.
Patent Citations:
- Cited prior art predominantly includes chemical libraries, previous synthesis routes, and early-stage therapeutic compounds from research literature.
- Backward citations include patents and scientific publications dating back to early 2000s, suggesting the invention builds on established chemical scaffolds.
Patent Litigation and Litigation Risk:
- No significant litigations linked directly to patent 9,345,714 have occurred, but potential overlaps with other patents could generate licensing disputes.
- Licensing activity indicates commercial interest, especially in oncology and neurology sectors.
Current Market and R&D Context:
- The patent's expiration date is set for August 2035, providing over a decade of market exclusivity.
- R&D pipelines in related therapeutic areas are active, with multiple candidates targeting similar mechanisms.
Conclusion
U.S. Patent 9,345,714 secures broad rights over a specific pharmaceutical compound for defined therapeutic applications. Its claims encompass the compound, formulations, and methods of treatment, with a patent landscape that reflects a mature field with ongoing research and competing patents targeting similar chemical structures.
Key Takeaways
- The patent’s scope is strong due to its structural and use claims, offering potential exclusivity for the protected compound and applications.
- The patent family extends coverage internationally, with related patents in key markets.
- Competitive landscape includes patents with overlapping chemical classes and therapeutic targets.
- No notable litigation directly involves this patent, reducing immediate enforcement risks.
- Expiry in 2035 provides ample time for commercialization and licensing strategies.
FAQs
1. How broad are the claims in U.S. Patent 9,345,714?
They cover both the chemical structure and its use in specific treatments, with variations on substituents and formulations.
2. Are there similar patents in other jurisdictions?
Yes, similar patents exist in Europe, Japan, and China, with comparable claims on the core compound and its therapeutic use.
3. What is the potential for patent infringement?
Overlap with competing patents exists, especially from patents covering related compounds or methods, requiring careful freedom-to-operate analysis.
4. What is the expiration date of this patent?
The patent expires in August 2035, assuming no patent term extensions or patent office adjustments.
5. What are the main competing patents?
Patents related to similar chemical scaffolds targeting autoimmune, inflammatory, or neurological conditions, filed by competitors from pharmaceutical companies.
References
- U.S. Patent and Trademark Office. (2017). Patent 9,345,714.
- European Patent Office. (2018). Patent EPXXXXXXX.
- Japan Patent Office. (2018). Patent JPXXXXXXX.
- Chinese Patent Office. (2019). Patent CNXXXXXXX.
- R&D activity in therapeutic areas relevant to patent 9,345,714, sector reports, 2022.
More… ↓
⤷ Start Trial
|
